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The results of a genomewide scan for genes conferring susceptibility to anxiety disorders in the Icelandic population
are described. The aim of the study was to locate genes that predispose to anxiety by utilizing the extensive
genealogical records and the relative homogeneity of the Icelandic population. Participants were recruited in two
stages: (1) Initial case-identification by a population screening for anxiety disorders, using the Stamm Screening
Questionnaire, was followed by aggregation into extended families, with the help of our genealogy database; and
(2) those who fulfilled the diagnostic and family aggregation criteria underwent a more detailed diagnostic workup
based on the Composite International Diagnostic Interview. Screening for anxiety in close relatives also identified
additional affected members within the families. After genotyping was performed with 976 microsatellite markers,
affected-only linkage analysis was done, and allele-sharing LOD scores were calculated using the program Allegro.
Linkage analysis of 25 extended families, in each of which at least one affected individual had panic disorder (PD),
resulted in a LOD score of 4.18 at D9S271, on chromosome 9q31. The intermarker distance was 4.4 cM on
average, whereas it was 1.5 cM in the linked region as additional markers were added to increase the information
content. The linkage results may be relevant not only to PD but also to anxiety in general, since our linkage study
included patients with other forms of anxiety.
Introduction
Anxiety disorders, often accompanied by depression, are
health care problems of major concern worldwide (Mur-
ray 1996; Rice et al. 1998). Because of their high prev-
alence, early onset (usually midadolescence through the
mid-20s), and chronic course, they cause as many dis-
ability days as do mood disorders (Andrews et al. 2001).
The U.S. National Comorbidity Study showed the lifetime
prevalences for panic disorder (PD [MIM 167870]) as
3.5/100, agoraphobia as 6.7/100, social phobia as 13.3/
100, and generalized anxiety disorder (GAD) as 5.1/100
(Kendler 1994). The lifetime prevalences of these disor-
ders in Iceland are within similar ranges (Lindal et al.
1993). The total lifetime prevalence of anxiety disorders
is estimated to be 15%–18%, and anxiety disorders are
more common among females. The treatment prevalence
of anxiety disorders appears to be increasing (Skaer et
al. 2000). Anxiety-disorder subtypes only rarely present
alone, and comorbidity is almost the rule (Goldenberg
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et al. 1996). The most common comorbid conditions are
other anxiety disorders, unipolar and bipolar mood dis-
orders, and substance abuse (George et al. 1990; Hunt
et al. 1995; Mineka 1998).
The etiology of anxiety disorders is complex, and eti-
ological factors have been sought in the field of genetics,
as well as in the environment (Hettema et al. 2001). It
has been debated whether the anxiety disorders are eti-
ologically distinct from each other or whether there are
anxiety traits with shared etiological factors (Skre et al.
1993; Kendler et al. 1995; Muris et al. 2001a; Stewart
et al. 2001). Results of family studies have consistently
demonstrated that PD runs in families. Twin studies in-
dicate that genetic variation contributes to this famili-
ality, even though no specific susceptibility genes have
been isolated (Finn and Smoller 2001). Irrational fears
and phobias, as well as GAD, also appear to have a
distinct genetic component, but environmental factors
also play a role (Hettema et al. 2001; Kendler et al. 2001).
The high comorbidity among the anxiety disorders and
between anxiety and mood disorders suggests a unifying
factor in their etiologies (Eley and Stevenson 1999).
Whereas phobias—and, in particular, PD—are strongly
familial, previous work clearly shows that individual
clinical phenotypes do not run true within families; rath-
er, the inheritance pattern strongly suggests that there
exist genetic factors that are common among the differ-
ent types of anxiety and perhaps even among their other
comorbid conditions.
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The genetic basis of anxiety remains to be discov-
ered. Numerous association studies have typically fo-
cused on genes involved in neurotransmission, such as
receptors and transporters, as well as enzymes involved
in synthesis or degradation of neurotransmitters (Maz-
zanti et al. 1998; Ohara et al. 1998; Nakamura et al.
1999; Sand et al. 2000; Hatton et al. 2001; Hamilton et
al. 2002). Although most results provide no support for
association or are inconclusive, there are some promising
results, such as for the catechol-O-methyltransferase lo-
cus, on chromosome 22 (Hamilton et al. 2002). Linkage
studies focusing on PD (Knowles et al. 1998; Crowe et
al. 2001) have identified some regions of potential inter-
est but so far have not yielded significant linkage. Al-
though most of the work has focused on PD, there are
some studies on a broader phenotype. For example,
chromosome 13 has been implicated in a linkage study
of a syndrome that includes PD and several medical
disorders (Weissman et al. 2000); suggestive loci have
been detected in a linkage study of PD and agorapho-
bia (Gelernter et al. 2001); and a polymorphic dupli-
cation on chromosome 15 has been identified as a sus-
ceptibility factor for PD, phobic disorders, and joint
laxity (Grataco`s et al. 2001).
Here, we present the linkage results for 62 families
altogether comprising 161 affected individuals, as deter-
mined on the basis of the broader phenotype of anxiety,
and linkage results for a subset of 25 families (67 affect-
ed), each with at least one index case diagnosed as PD,
in addition to individuals with other forms of anxiety.
In defining the broader phenotype of anxiety, we decid-
ed to include the phobias, other anxiety disorders, GAD,
and somatoform pain. The last two may be a debatable
inclusion. GAD, typically classified with the anxiety dis-
orders, has also been closely linked with depression. The
distinction relies at least partly on the emphasis given
common genetic versus environmental factors, as re-
viewed in two recent articles (Kessler 2000; Hunt 2002).
In the total sample, of those with GAD, 41% are comor-
bid with PD, and 43% are comorbid with depressive
disorders; 14% of those with GAD are comorbid with
both PD and depressive disorders. Persistent somatoform
pain has, as does GAD, a close relationship to both de-
pression and anxiety (Von Korff et al. 1996); further-
more, Muris et al. (2001b) have found a close relation-
ship between anxiety sensitivity and pain anxiety, which
again may lead to chronic-pain complaints. In the present
sample, persistent somatoform pain was highly comorbid
with other anxiety disorders, and the average age at its
onset (20.7 years) was in the same range as PD and the
phobias. On the basis of this finding, we decided to in-
clude somatoform pain in our linkage analysis. The pres-
ent study is based on a population sample, first screened
for anxiety, then further classified with a more detailed
diagnostic workup, and clustered into families by using
a comprehensive genealogy database.
Material and Methods
Population Screening and Genealogy Work
The National Bioethics Committee and the Data Pro-
tection Commission of Iceland approved the study. The
initial sample is based on a population screening for
anxiety by mail. All person-identifying data were en-
crypted by the Data Protection Commission of Iceland,
using a third-party encryption system developed by de-
Code Genetics (Gulcher et al. 2000). The Stamm Screen-
ing Questionnaire (SSQ), accompanied by a detailed de-
scription of the study, was mailed to a population sample
of 9,992 randomly selected individuals, of 18–60 years
of age. This questionnaire screens for lifetime occurrences
of anxiety and mood disorders and is based on the Com-
posite International Diagnostic Interview (CIDI) (Peters
and Andrews 1995; Wittchen et al. 1996). The SSQ has
16 questions probing for the lifetime history of anxiety,
mood, and addictive disorders. We relied on answers to
five anxiety questions (appendix A); the PD question was
the key one, added to which was the accumulated score
of four other anxiety questions (GAD, social phobia, sim-
ple phobia, and agoraphobia). This formed the basis for
our definition of an index case. Those who fulfilled the
case-definition criteria for anxiety were clustered accord-
ing to family relatedness, with the help of a population-
wide genealogy database (Gulcher et al. 1998). The en-
crypted list of those meeting the SSQ criteria was analyzed
through the genealogy database, using recursive algo-
rithms to find all ancestors related to those on our en-
crypted list, given a number of generations. The cluster
function then searched for ancestors common to any two
or more members on the encrypted list, automatically
generating extended pedigrees. For a family to be re-
cruited for our linkage analysis, it needed to contain at
least one proband scoring positively for panic attack
and, in addition, positively for at least two of the four
remaining anxiety questions (GAD and the three pho-
bias). Individuals responding positively to one or two
SSQ anxiety questions were also included if they were
related to an index case subject as defined above.
The results of the search identified potential fami-
lies that were defined by a genealogical relationship
between affected family members within a distance of
5 meiotic events (i.e., first cousins, once removed).
During the recruitment process, individuals from these
families were invited to participate. Having signed in-
formed consent forms, the participants underwent a
further diagnostic evaluation based on the CIDI and
donated a blood sample. The CIDI yields both DSM-
III-R and ICD-10 lifetime diagnoses. In our linkage
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analysis, we combined the results of these two diagnos-
tic systems such that each index case subject received
one diagnosis for each disorder, and we did not sepa-
rately analyze, for linkage, the data based on each di-
agnostic system. After the administration of the CIDI,
each index case subject was asked to refer to the study
any relative who possibly has an anxiety disorder. Rel-
atives testing positive for anxiety by the SSQ were then
invited to enter into the study as potential index case
subjects and underwent the same procedures as the par-
ticipants recruited through the initial SSQ survey. Blood
samples were also collected from additional first-degree
relatives, regardless of affected status, to ascertain to
what extent the genetic make-up of an index case sub-
ject derives from each parent.
Microsatellite Markers and Genotyping
We genotyped 353 individuals (161 affected and 192
relatives) in 62 families, and we used a marker set, devel-
oped at deCode Genetics, that contains markers from the
ABI Linkage Marker (version 2) screening and intercalat-
ing sets, as well as 500 custom-made markers. The set
uses 976 fluorescently labeled primers with an initial ge-
nomewide average spacing of 3.8 cM. The set has been
extensively tested for multiplex PCR results. PCR ampli-
fications were set up, run, and pooled on Gilson Cyberlab
robots. The reaction volume was 5 ml, and, for each PCR,
20 ng of genomic DNA was amplified in the presence of
2 pmol of each primer, 0.25 U AmpliTaq Gold, 0.2 mM
dNTPs, and 2.5 mM MgCl2 (buffer was supplied by the
manufacturer, Applera). Cycling conditions were as fol-
lows: 95C for 10 min, followed by 37 cycles of 94C for
15 s, annealing for 30 s at 55C, and 1 min extension at
72C. The PCR products were supplemented with the
internal size standard, and the pools were separated and
detected on 3700 Sequencers by using Genescan (version
3.0) peak-calling software (Applera). The genotypes for
a total of 867 markers from the genomewide set were
used for the linkage analysis, resulting in an average in-
termarker distance of 4.4 cM. Alleles were automatically
called using DAC, an allele-calling program developed at
deCode Genetics (Fjalldal et al. 2001), and the program
DecodeGT was used to fractionate called genotypes, ac-
cording to quality, and to edit when necessary (Pa´lsson
et al. 1999).
Statistical Methods for Linkage Analysis
To evaluate linkage, we used multipoint, affected-
only allele-sharing methods. The program Allegro (Gud-
bjartsson et al. 2000) was used for the calculation of
NPL and LOD scores. We employed the Spairs scoring
function (Whittemore and Halpern 1994; Kruglyak et
al. 1996) and the exponential allele-sharing model (Kong
and Cox 1997) to generate the relevant test statistics.
Family scores were combined to obtain an overall score,
using a weighting scheme that, on the log scale, is half-
way between weighting the families equally (Kruglyak
et al. 1996) and weighting the affected pairs equally,
with the resulting weighting scheme being equal to the
geometric mean of the two schemes. This scheme gives
weights similar to those proposed by Weeks and Lange
(1988) as an extension of the scheme that Hodge (1984)
designed for sibships.
In addition to requiring the pointwise P value to be
! (Lander and Kruglyak 1995), we consider52# 10
the linkage results to be significant only if the informa-
tion content in the region is 85%. Information con-
tent is calculated as follows. On the basis of the expo-
nential model described by Kong and Cox (1997), the
actual LOD score is obtained, in part, by maximizing
the likelihood with respect to a scalar parameter, d, that
measures the amount of excess identity-by-descent shar-
ing among affected relatives, with correspondingdp 0
to the null hypothesis. A corresponding, “predicted”
LOD score can be calculated by considering the hypo-
thetical situation in which the information is complete
but the maximum-likelihood estimate of d remains the
same. This predicted LOD score is, in general, larger
than the actual LOD score, and the information content
is defined as the ratio of the actual LOD score to the
predicted LOD score. Note that, when this definition is
used, information content can be applied even to a locus
with no excess sharing by allowing the maximum-like-
lihood estimate of d to be negative. The singularity that
occurs at , leading to division by 0, is resolved bydp 0
the application of L’Hopital’s rule. This information
measure, implemented in Allegro, was introduced and
studied in detail by Nicolae (1999), who demonstrated
that it is asymptotically equivalent to a classic measure
of information, as described by Dempster et al. (1977).
This measure has the property that it lies between 0, if
the marker genotypes are completely uninformative, and
1, if the genotypes determine the exact amount of allele
sharing by descent among the affected relatives. The
marker order and positions used in linkage analysis are
from our high-resolution genetic map (Kong et al. 2002).
Results
Population Survey and Family Data
Valid responses were sent in by 2,792 respondents.
There were no large differences in terms of age, sex,
or urban/rural domicile between respondents and non-
respondents. A total of 1,783 individuals, or 64%, gave
a positive answer to one or more of the five SSQ anxiety
items used. Because the response rate was 28%, the re-
sults of the survey can by no means be interpreted as a
measure of population prevalence; instead, they most
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Table 1
Characteristics of the Members of the Families with Anxiety or PD
DIAGNOSIS
RESULTS FOR FAMILIES WITH
Anxiety (62 Families) PD (25 Families)
PD 29 (18) 29 (43)
GAD 53 (33) 28 (42)
Agoraphobia 40 (25) 23 (34)
Social phobia 81 (50) 38 (56)
Simple phobia 54 (33) 26 (39)
Other anxiety 27 (17) 14 (21)
Persistent somatoform pain 76 (47) 26 (39)
Average no. of anxiety disorders 2.2 2.7
Dysthymia 30 (19) 20 (30)
Depression 83 (52) 45 (67)
Average age at interview 40.6 years 38.8 years
Male:female ratio 1:2.9 1:7.4
NOTE.—Except as otherwise indicated, data are given as no. (%).
Table 2
Characteristics of the Members of the 25 Families with PD
DIAGNOSIS
RESULTS FOR FAMILY MEMBERS
With PD Without PD
PD 29
Anxiety disorders without PD: 38
Subclinical PD 0 12 (32)
GAD 16 (55) 12 (32)
Agoraphobia 16 (55) 7 (18)
Social phobia 19 (66) 19 (50)
Simple phobia 14 (48) 12 (32)
Other anxiety 8 (28) 6 (16)
Persistent somatoform pain 12 (41) 14 (37)
Average no. of anxiety disorders:
Including PD and subclinical PD 3.9 2.2
Excluding PD and subclinical PD 2.9 1.9
Dysthymia 10 (35) 10 (26)
Depression 20 (70) 25 (66)
Average age at interview 35.1 years 41.7 years
Male:female ratio 1:6.3 1:8.5
Age at onset of PD 18.1 years
NOTE.—Except as otherwise indicated, data are given as no. (%).
likely represent a cohort biased toward those affected
with anxiety. Analysis of those who fulfilled our case-
definition criteria for anxiety through the genealogy da-
tabase revealed that a total of 490 positive respondents
were clustered in 73 families consisting of at least two
members.
As a result of the population survey, we were able
to identify and focus our initial sample collection on
the families most likely to carry the highest load of PD.
However, although the SSQ questionnaire is a sensitive
tool, it does not yield specific diagnoses. After the CIDI,
many of the families turned out to have no members with
DSM-III-R or ICD-10 PD, although approximately two-
thirds of the potential index case subjects received one or
more CIDI anxiety diagnoses. Diagnostic congruence be-
tween ICD-10 and DSM-III-R varied. The DSM-III-R
was more likely to produce phobia diagnoses, whereas
the ICD-10 produced a higher number of depressive dis-
orders. We found this to be an acceptable false-positive
rate, and we have now expanded our sample collection
to include, in a similar manner, both GAD and the pho-
bias. Currently, 1,040 CIDIs have been administered, re-
sulting in anxiety diagnoses in 646 individuals.
For the present study, a total of 161 affected individuals
within 62 families were identified. We also analyzed link-
age for a part of the linkage cohort—namely, 25 families
centered on individuals with PD. Each of these families
included an index case subject with a DSM-III-R or ICD-
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Table 3
Results of Genomewide Scans for PD and Anxiety
CHROMOSOME
MAXIMUM ALLELE-SHARING LOD
SCORE, FOR FAMILIES WITH
POSITION
(Kosambi cM)
RANGE, FOR LOCI
WITH LOD  1.0
(cM) PEAK MARKER(S)Anxiety (62 Families) PD (25 Families)
3 1.24 52.6 43–54 D3S1266, D3S3547
3 1.81 54.6 41–57 D3S3547
3 1.08 106.6 100–107 D3S3653, D3S3508
4 1.37 100.2 74–101 D4S423
8 1.26 61.6 56–64 D8S532, D8S531
9 2.00 104.1 93–111 D9S1690
9 4.18a 105.6 79–113 D9S1690, D9S271
10 1.19 144.6 140–146 D10S1230
15 1.11 112.7 108–119 D15S157
18 1.09 32.4 28–35 D18S464
18 1.06 103.9 98–q-ter D18S469
X 1.47 141.1 122–157 DXS1062
a Additional markers were genotyped in the linkage region on chromosome 9q, with a resulting average intermarker distance of 1.5 cM
(information content 85%).
10 diagnosis of PD and relatives with any anxiety disorder
at a genealogical distance of 5 meiotic events. Table 1
details some characteristics of both sets of families and
the distribution of diagnoses.
Table 2 shows some characteristics of the affected
members of the 25 families with PD, for those indi-
viduals with and without PD. The distribution of anx-
iety and depression diagnoses clearly shows that co-
morbidity was the rule, rather than the exception. The
average age at the time of interview was higher in those
family members who did receive a diagnosis of PD. This
should have given them a chance to develop more psy-
chopathology, particularly in the range of depressive
illnesses, but analysis of comorbidity reveals that this
is not the case. The prevalence in females is higher
(male:female ratio 1:7.4) in these families than in our
total sample (male:female ratio 1:2.9), both in those
affected with PD and those affected with other anxiety
disorders only. This is an interesting observation, but,
because the numbers are small, we refrain from draw-
ing any conclusion from this.
The average number of anxiety diagnoses, even when
PD is excluded, is higher in the group with PD as com-
pared to family members without PD. This applies to
all the anxiety disorders, with the difference being most
marked in agoraphobia. Thus, having PD increases the
risk of additional anxiety comorbidity. The mood-dis-
order prevalence in these families is similar for those
with and without PD, but the rate is much higher than
that in the general population, as indicated by the life-
time prevalence of depression in Iceland, which has
been estimated at 11% (Lindal and Stefansson 1991).
The trend is clear—namely, having one anxiety disor-
der, particularly having PD, leads to a high risk of de-
veloping other anxiety and mood disorders.
Linkage Analysis
Only those with DSM-III-R or ICD-10 anxiety di-
agnoses are considered to be affected in the linkage
analysis, and the remaining family members are con-
sidered to have “unknown” affected status for linkage
analysis. The diagnoses leading to affected status are
given in table B1 (see appendix B). As has been ex-
plained above (see the “Material and Methods” sec-
tion), the families were constructed on the basis of a
genealogical distance of 5 meiotic events, and, there-
fore, each member was related to at least one other
affected member at that or a lower distance. However,
the distance between some pairs was higher, and such
pairs were also included in the linkage analysis. The
positions of all the loci with LOD scores 1.0 in the
linkage analysis using the framework markers are shown
in table 3, for both sets of families. The analysis for the
broad phenotype of anxiety revealed a suggestive locus
(LOD p 2.00) at D9S1690 (104.1 cM) and several
regions with LOD scores of 1.0–2.0 (table 3).
Figure 1 shows the LOD scores from the genome-
wide scan for the families with PD. The 25 families
with PD have two to five affected members and they
provide 60 different affected relative pairs with an
average genealogical distance of 3.6 meiotic events.
Of the affected relative pairs, only three involve two
patients with PD, and the remaining pairs have one
member with PD (41 pairs) or neither member with
PD (16 pairs). Six regions achieved allele-sharing LOD
scores 11.0, and the highest LOD score was 3.89, on
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Figure 1 Results of genomewide linkage analysis of 25 families (67 affected members), using a multiplexed framework set of 976
markers. The genotypes of 867 markers were used for analysis, resulting in an average intermarker distance of 4.4 cM. The multipoint
allele-sharing LOD score is shown on the Y-axis, and the distance (in Kosambi cM) from the p-terminus of each chromosome is shown on
the X-axis.
chromosome 9 (104.1 cM). We genotyped additional
markers in this locus, to bring the information content
to 85%. The resulting average intermarker distance
was 1.5 cM. Figure 2 depicts the resulting LOD scores
on chromosome 9. Linkage analysis using genotypes
for the high-density map resulted in a LOD-score maxi-
mum of 4.18, at 105.6 cM (D9S271), with an informa-
tion content of 85%. Although the locus is fairly wide
(the LOD score is 11.0 in the region between 79 and
113 cM), the curve is somewhat asymmetric, and the
LOD score drops rapidly distal to its maximum. The
pointwise P value for the locus was , which66# 10
corresponds to a genomewide adjusted P value !.05
(Lander and Kruglyak 1995). The correction for mul-
tiple testing is small, since only two complete scans were
performed, and the adjusted P value remains !.05. No
single family is responsible for the LOD score, and 14
of the 25 families have more sharing than had been
expected on the basis of their familial relationship alone,
at D9S271. Correspondingly, of the 62 families with
anxiety, 30 have excess sharing at D9S1690. No other
region had LOD scores reaching suggestive levels, but
additional regions with maximum LOD scores near 1.0
were observed on five chromosomes: X, 3, 4, 15, and
18 (see fig. 1 and table 3).
Discussion
We have detected linkage of PD and anxiety to chro-
mosome 9q31, with a LOD score of 4.18, in Icelandic
families centered on probands with PD. The linked re-
gion has a suggestive LOD score of 2.0 in a larger set
of families defined by the broader phenotype of anxiety.
Although the linkage appears to be strong, the finding
should be questioned until it has been replicated, both
in additional families from the present study in Iceland
and in other populations. The families with PD were col-
lected in an effort whose focus was PD, but more than
half of the affected family members had other forms of
anxiety without a diagnosis of PD. Whereas all the af-
fected members of these families are related to a proband
with PD, only 3 of the 60 affected relative pairs in the
linkage analysis involve pairs in which both individuals
received a diagnosis of PD. Furthermore, most of the
affected members diagnosed with PD have also received
other anxiety diagnoses. It is therefore just as likely that
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Figure 2 Multipoint allele-sharing LOD scores for chromosome 9, using a higher-resolution map. With an average intermarker distance
of 1.5 cM in the linked region, a multipoint LOD score of 4.18 was detected at marker D9S271 (105.6 cM). The multipoint allele-sharing
LOD score is shown on the Y-axis, and the distance (in Kosambi cM) from the p-terminus is shown on the X-axis.
the linkage results are due to a gene that plays a role in
susceptibility to anxiety in general, rather than to PD
only. However, although 38 affected members did not
receive a diagnosis of PD, some may have experienced
symptoms of PD or may develop PD later in life. The
families were collected on the basis of the SSQ question
relating to PD, and, of the 38 without PD, 12 (32%)
reported symptoms of PD without fulfilling all the cri-
teria for diagnosis of PD by ICD-10 or DSM-III-R.
Previous genomewide scans have focused on PD,
with the exception of one study on PD and agora-
phobia (Gelernter et al. 2001). Several loci have been
reported, but, to our knowledge, none has reached
genomewide significance. A region on chromosome
7p has been implicated twice (Knowles et al. 1998;
Crowe et al. 2001), with parametric LOD scores near
2, but the nonparametric LOD score for this region
was 0 in the present study. The same holds true for
most loci that have previously been reported, but three
regions with LOD scores near 1.0 in the present study
have been described elsewhere: The peak on chromo-
some 4 has a LOD-score maximum at 78 cM, and the
region (75–105 cM) overlaps with that reported by
Gelernter et al. (2001) for agoraphobia. The region on
Xq, with a LOD score of 1.47, also overlaps with a
region reported by Gelernter et al. (2001) for PD, ag-
oraphobia, and both phenotypes combined. The third
region, on chromosome 15q, with a LOD score of 1.0,
is just telomeric to the position of DUP25, a recently
identified duplication that is associated with PD, pho-
bias, and joint laxity in a Spanish population (Grataco`s
et al. 2001).
Although LOD scores !2.0 are far from significant
in a genomewide linkage scan, it is possible that some
of them represent true anxiety-susceptibility loci, par-
ticularly when the regions have been indicated in other
studies. That we have detected three such regions in
addition to the strong linkage to chromosome 9q may
reflect an underlying genetic heterogeneity of anxiety
disorders. Interestingly, the overlapping regions are
from previous studies involving not only PD but also
other forms of anxiety.
Although it is most likely that the linkage is due to
a gene that renders susceptibility to multiple forms of
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anxiety, alternative explanations are possible. It is, for
example, possible that the linkage is specific to con-
ditions related to PD. If this were the case, the phe-
notype involved would not be PD as defined by the
ICD-10 or DSM-III-R systems; rather, it would com-
prise particular symptoms related to PD, such as the
occurrence of a panic attack. The material that we have
so far analyzed does not grant enough power to ex-
tensively fractionate the phenotypes for analysis, and,
because of the high comorbidity among the anxiety dis-
orders, their relative contributions to the linkage cannot
be estimated. The same holds true for depression, and,
formally, it cannot be ruled out that the linkage is to
depression and related conditions, since both depression
and GAD are enriched in the families with PD. We are,
however, in the process of collecting and genotyping
additional families with PD, as well as families found
on the basis of answers to the SSQ questions relating
to GAD and the phobias. We hope to be able to address
the issue of subphenotypes after the analysis of linkage
in these families. The analysis of phenotypes of the in-
dividuals so far identified clearly shows a high level of
comorbidity among the different anxiety disorders and
shows that families in which anxiety subtypes are seg-
regating separately are rarely observed. These observa-
tions may reflect variable expressivity of each underly-
ing anxiety gene within the same family, as is seen for
numerous Mendelian disorders. In conclusion, the most
reasonable explanation of our results is that the sub-
types of anxiety are all complex disorders sharing some
but not necessarily all susceptibility genes and that the
locus at chromosome 9q31 most likely harbors a sus-
ceptibility gene for both PD and other forms of anxiety.
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Appendix A
Stamm Screening Questionnaire (SSQ)
Following are English translations of the five anxiety
questions used following our population screening for
anxiety when defining cases for the genealogy analysis.
The SSQ was translated from German to Icelandic and
was then back-translated; the English translation is ours
and has not been back-translated.
● Panic attacks.—Have you ever had an anxiety at-
tack, sometimes called “panic attack” or “fear,” dur-
ing which you suddenly were overwhelmed by feel-
ings of intense fear, sadness, or uptightness?
● Generalized anxiety disorder.—Have you ever during
your lifetime experienced a period of one month or
longer during most of which you felt anxious, tense,
or filled with worries?
● Social phobia.—Have you ever suffered from unrea-
sonable intense fear in social situations, such as
talking to others, to do certain things in the pres-
ence of others, or to be the center of attention?
● Agoraphobia.—Have you ever suffered from unrea-
sonable intense fear when using public transpor-
tation, going shopping, waiting in line, or being in
public places?
● Simple phobias.—Have there ever been periods of
time during which you suffered from unreasonable
intense fear of other situations (closed spaces) or
things (heights, bad weather, animals)?
Appendix B
Table B1
ICD-10 and DSM-III-R Codes Used in the Assignment of Affected
Status
DISORDER
CODE(S)
ICD-10 DSM-III-R
Panic disorder F40.01, F41.00, F41.01 300.01, 300.21
Anxiety:
Generalized anxiety
disorder F41.10, F41.11, F41.2 300.02
Agoraphobia F40.00, F40.01 300.21, 300.22
Social phobia F40.1 300.23
Simple phobia F40.2 300.29
Other anxiety
disorder F41.8, F44 300.1, 300.6–8
Somatoform pain F45.4 307.8
Depression F32, F33 296.3, 296.4
Electronic-Database Information
The URL for data presented herein is as follows:
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for PD)
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